Pre-market Hot Trades in US Stocks
CBRL pre-market down 9.26%. According to recent key news:
<ol>
<li>
On September 18, Cracker Barrel Company projected fiscal year 2026 revenue below analyst expectations, causing the stock price to drop about 9.5% after hours. The company expects adjusted EBITDA to be between $150 million and $190 million, down from $224.3 million in 2025. Data source: LSEG.
</li>
<li>
On September 18, the company expects same-store traffic to decline by 4% to 7% this fiscal year and faces the dilemma of revenue falling short of expectations. A previous logo change plan sparked consumer dissatisfaction, leading to further declines in stock price. Data source: WSJ.
</li>
<li>
On September 18, Cracker Barrel faces a $25 million financial impact from tariffs imposed by the Trump administration, forcing the company to reduce the number of products in its gift shop and renegotiate deals. Data source: Benzinga. The industry is facing policy changes, with active capital flows.
</li>
</ol>
ATIF pre-market up 8.48%. According to recent key news:
<ol>
<li>
On September 18, ATIF Holdings announced the signing of a non-binding letter of intent to acquire 100% of Mask Global Market's equity by issuing Class A common stock of ZBAI. This move aims to integrate Web2 and Web3 technologies, driving the stock price up 36% in after-hours trading. Data source: MT Newswires.
</li>
<li>
On September 17, ATIF Holdings signed a letter of intent with Mask Global Market, stipulating a 60-day exclusivity negotiation period, restricting both parties from engaging in similar transactions with other companies. This news propelled the stock price upward. Data source: Reuters.
</li>
<li>
On September 18, ATIF Holdings' stock price surged 39% in after-hours trading to $15.25, reflecting the market's positive response to its acquisition plan. Data source: Press Release. Industry consolidation drives stock price volatility.
</li>
</ol>
Top Gainers in Pre-market US Stocks
89bio pre-market up 82.55%. Based on recent important news:
<ol>
<li>
On September 18, Roche announced it would acquire 89bio for $14.50 per share in cash, with a total transaction value of up to $3.5 billion. This news significantly boosted 89bio's stock price. Data source: Zhitong Finance.
</li>
<li>
On September 18, 89bio's key drug pegozafermin is in late-stage development and is expected to become the best therapy for treating metabolic dysfunction-associated fatty liver disease. The drug's potential has attracted market attention. Data source: Zhitong Finance.
</li>
<li>
On September 18, Roche plans to accelerate the development of its experimental weight loss drug, further enhancing its competitiveness in the obesity treatment market. This strategic move has increased investor confidence in 89bio
Data source: Zhitong Finance. The biopharmaceutical industry is active in mergers and acquisitions.
</li>
</ol>
Aptevo Therapeutics pre-market rose 55.32%. Based on recent important news:
<ol>
<li>
On September 16, Aptevo Therapeutics announced that the third cohort of its Phase 1b/2 RAINIER trial for acute myeloid leukemia (AML) achieved a 100% remission rate, leading to a 57% increase in stock price. The trial tested Aptevo's CD123 x CD3 bispecific antibody in combination with venetoclax and azacitidine for newly diagnosed AML patients.
</li>
<li>
On September 16, Aptevo's stock trading volume surged, with approximately 34 million shares changing hands, compared to an average of about 165,000 shares over the past three months, indicating a strong market reaction to the company's news.
</li>
<li>
On September 17, despite facing financial challenges, including declining revenue and negative cash flow, Aptevo's positive progress in its oncology pipeline provides potential upside for the future. The biotechnology industry is highly volatile and requires caution.
</li>
</ol>
AquaBounty Technologies pre-market rose 52.63%. Based on recent key news:
<ol>
<li>
On September 18, technical analysis showed a neutral outlook, with mixed momentum indicator signals. The negative price-to-earnings ratio and lack of dividends further affected the stock's attractiveness. Improvements in operational efficiency and cash flow management are crucial for enhancing its financial health.
</li>
<li>
On September 18, AquaBounty Technologies focuses on developing and commercializing genetically modified fish to improve aquaculture productivity.
</li>
<li>
On September 18, the current market capitalization is $4.3 million, with an average trading volume of 2,134,395. The biotechnology industry has shown recent volatility
</li>
</ol>

CBRL

ZBAI

CB Rural Store pre-market down 9.26%; ATIF pre-market up 8.48%; 89bio pre-market up 82.55%; Aptevo Therapeutics pre-market up 55.32%; AquaBounty Technologies pre-market up 52.63%

Pre-market hot trades in US stocks: CB CBRL pre-market down 9.26%; ATIF pre-market up 8.48%